Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Has Consensus Price Target of $32.83

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $32.83.

CRVS has been the subject of several research reports. Ladenburg Thalmann & Co. Inc. raised Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. Mizuho set a $27.00 price target on Corvus Pharmaceuticals in a research report on Thursday, October 29th. Finally, Wall Street Zen cut Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th.

View Our Latest Analysis on Corvus Pharmaceuticals

Corvus Pharmaceuticals Trading Down 1.8%

CRVS opened at $10.01 on Tuesday. Corvus Pharmaceuticals has a twelve month low of $6.39 and a twelve month high of $26.95. The company’s 50-day moving average price is $10.91 and its two-hundred day moving average price is $13.83.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Sell-side analysts expect that Corvus Pharmaceuticals will post -0.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jeffrey Arcara acquired 3,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average cost of $11.46 per share, for a total transaction of $34,380.00. Following the purchase, the insider owned 3,000 shares of the company’s stock, valued at approximately $34,380. The trade was a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders bought 4,500 shares of company stock valued at $50,478. Company insiders own 19.70% of the company’s stock.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRVS. Algert Global LLC bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth approximately $164,000. Virtu Financial LLC purchased a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $147,000. Entropy Technologies LP bought a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at $384,000. Jump Financial LLC raised its holdings in Corvus Pharmaceuticals by 12.3% during the 3rd quarter. Jump Financial LLC now owns 351,859 shares of the company’s stock valued at $4,053,000 after acquiring an additional 38,459 shares during the period. Finally, Marshall Wace LLP raised its holdings in Corvus Pharmaceuticals by 27.8% during the 3rd quarter. Marshall Wace LLP now owns 128,448 shares of the company’s stock valued at $1,480,000 after acquiring an additional 27,974 shares during the period. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

Featured Stories

Analyst Recommendations for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.